Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 September;63(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 September;63(3):271-7

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW  RAI THERAPY IN ADVANCED DIFFERENTIATED THYROID CANCER: FOCUS ON DOSIMETRY Freefree

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 September;63(3):271-7

DOI: 10.23736/S1824-4785.19.03202-3

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Physics aspects of setting up a multicenter clinical trial involving internal dosimetry of radioiodine treatment of differentiated thyroid cancer

Jan TAPROGGE 1, 2 , Francesca LEEK 1, 2, Glenn D. FLUX 1, 2

1 Joint Department of Physics, Royal Marsden NHS Foundation Trust, Sutton, UK; 2 The Institute of Cancer Research, London, UK



The field of molecular radiotherapy is expanding rapidly, with the advent of many new radiotherapeutics for the treatment of common as well as for rare cancers. Treatment outcome is dependent on the absorbed doses delivered to target volumes and to healthy organs-at-risk, which are shown to vary widely from fixed administrations of activity. There have been significant developments in quantitative imaging and internal dosimetry in recent years, although clinical implementation of these methods has been slow in comparison with external beam radiotherapy, partly due to there being relatively few patients treated at single centers. Multicenter clinical trials are therefore essential to acquire the data required to ensure best practice and to develop the personalized treatment planning that this area is well suited to, due to the unrivalled opportunity to image the therapeutic drug in vivo. Initial preparation for such trials requires a significant effort in terms of resources and trial design. Imaging systems in participating centers must be characterized and set up for quantitative imaging to allow for collation of data. Data transfer for centralized processing is usually necessary but is hindered in some cases by data protection regulations and local logistics. Recent multicenter clinical trials involving radioiodine therapy have begun to establish the procedures necessary for quantitative SPECT imaging in a multicenter setting using standard and anthropomorphic phantoms. The establishment of national and international multicenter imaging and dosimetry networks will provide frameworks to develop and harmonize best practice with existing therapeutic procedures and to ensure rapid and optimized clinical implementation of new radiotherapeutics across all centers of excellence that offer molecular radiotherapy. This will promote networks and collaborations that can provide a sound basis for further developments and will ensure that nuclear medicine maintains a key role in future developments.


KEY WORDS: Radionuclide imaging; Radioisotopes; Radiometry; Radiotherapy; Multicenter studies as topic

inizio pagina